BridgeBio Pharma, Inc. (BBIO) stock

BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 3/30

$78.30+0.13 (+0.17%)

Close on Nov 13, 2026Market cap $15.25BP/E –Yield –

BridgeBio Pharma price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

BridgeBio Pharma's price to sales ratio was 21.8× on Nov 11, 2026, against 39.2× a year earlier. Over the last 5 years it ranged from 12.8× to 482.2×, with a median of 27.6×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	21.8×	−19.9
2025	Dec 31, 2025	41.6×	+17.8
2024	Dec 31, 2024	23.8×	−48.4
2023	Jul 31, 2023	72.2×	+59.4
2022	Dec 30, 2022	12.8×	−30.2
2021	Dec 31, 2021	43.1×	−171.8
2020	Dec 31, 2020	214.8×	–

Where these numbers come from

Parsed from the XBRL in BridgeBio Pharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing